Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer (vol 26, pg 5544, 2008)

被引：0
|
作者：
Leo, Di
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 11期
关键词：
D O I：
10.1200/JCO.2009.22.9419
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1923 / 1923
页数：1
相关论文
共 50 条
  • [1] Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
    Di Leo, Angelo
    Gomez, Henry L.
    Aziz, Zeba
    Zvirbule, Zanete
    Bines, Jose
    Arbushites, Michael C.
    Guerrera, Stephanie F.
    Koehler, Maria
    Oliva, Cristina
    Stein, Steven H.
    Williams, Lisa S.
    Dering, Judy
    Finn, Richard S.
    Press, Michael F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (34) : 5544 - 5552
  • [2] Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III randomized, double-blind study of 580 patients
    Di Leo, A.
    Gomez, H.
    Aziz, Z.
    Zvirbule, Z.
    Arbushites, M.
    Oliva, C. R.
    Koehler, M.
    Williams, L. S.
    Dering, J.
    Finn, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] MERiDiAN: A phase III, randomized, double-blind study of the efficacy, safety, and associated biomarkers of bevacizumab plus paclitaxel compared with paclitaxel plus placebo, as first-line treatment of patients with HER2-negative metastatic breast cancer
    Miles, David
    Faoro, Leonardo
    Wang, Yan V.
    O'Shaughnerary, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Phase III trial evaluating paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer
    Tong, Zhongsheng
    Li, Shufen
    Shi, Yehui
    Wang, Xu
    Hao, Chunfang
    He, Lihong
    Dong, Guolei
    Wang, Xiaorui
    Jia, Yongsheng
    Zhang, Li
    CANCER RESEARCH, 2015, 75
  • [5] Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triplenegative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (vol 18, pg 1360, 2017)
    Kim, S. B.
    Dent, R.
    Im, S. A.
    LANCET ONCOLOGY, 2018, 19 (12): : E667 - E667
  • [6] Paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial.
    Tong, Zhongsheng
    Li, Shufen
    Shi, Yehui
    Wang, Xu
    Wang, Chen
    Hao, Chunfang
    Wang, Xiaorui
    Meng, Wenjin
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Lueck, Hans-Joachim
    Du Bois, Andreas
    Loibl, Sibylle
    Schrader, Iris
    Huober, Jens
    Heilmann, Volker
    Beckmann, Matthias
    Staehler, Ann
    Jackisch, Christian
    Hubalek, Michael
    Richter, Barbara
    Stickeler, Elmar
    Eidtmann, Holger
    Thomssen, Christoph
    Untch, Michael
    Wollschlaeger, Kerstin
    Schuster, Tibor
    von Minckwitz, Gunter
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 779 - 787
  • [8] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
    Hans-Joachim Lück
    Andreas Du Bois
    Sibylle Loibl
    Iris Schrader
    Jens Huober
    Volker Heilmann
    Matthias Beckmann
    Ann Stähler
    Christian Jackisch
    Michael Hubalek
    Barbara Richter
    Elmar Stickeler
    Holger Eidtmann
    Christoph Thomssen
    Michael Untch
    Kerstin Wollschläger
    Tibor Schuster
    Gunter von Minckwitz
    Breast Cancer Research and Treatment, 2013, 139 : 779 - 787
  • [9] Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Kim, Sung-Bae
    Dent, Rebecca
    Im, Seock-Ah
    Espie, Marc
    Blau, Sibel
    Tan, Antoinette R.
    Isakoff, Steven J.
    Oliveira, Mafalda
    Saura, Cristina
    Wongchenko, Matthew J.
    Kapp, Amy V.
    Chan, Wai Y.
    Singel, Stina M.
    Maslyar, Daniel J.
    Baselga, Jose
    LANCET ONCOLOGY, 2017, 18 (10): : 1360 - 1372
  • [10] Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
    Miles, David
    Cameron, David
    Bondarenko, Igor
    Manzyuk, Lyudmila
    Alcedo, Juan Carlos
    Lopez, Roberto Ivan
    Im, Seock-Ah
    Canon, Jean-Luc
    Shparyk, Yaroslav
    Yardley, Denise A.
    Masuda, Norikazu
    Ro, Jungsil
    Denduluri, Neelima
    Hubeaux, Stanislas
    Quah, Cheng
    Bais, Carlos
    O'Shaughnessy, Joyce
    EUROPEAN JOURNAL OF CANCER, 2017, 70 : 146 - 155
12345